SAN FRANCISCO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on February 25th by UNITY Biotechnology, Inc. [Nasdaq: UBX], please note that in the first paragraph of the release, financial results will be reported before Nasdaq market open, not after market close. The corrected release follows:

UNITY Biotechnology, Inc. to Announce Fourth Quarter and Full Year 2018 Financial Results

UNITY Biotechnology, Inc. (UNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report financial results for the fourth quarter and full year ended December 31, 2018, on Wednesday, March 6, 2019, before Nasdaq market open.

UNITY will not conduct a conference call in conjunction with the financial results press release.

About UNITY
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Media
Austine Graff
UNITY Biotechnology
707-593-6151
austine.graff@unitybiotechnology.com